본문 바로가기
KERD
논문KCI 등재

브린졸라미드 복합제의 개방각 녹내장 또는 고안압증에 대한 효과 및 안전성 검증: 체계적 문헌 고찰 및 메타분석 연구

Effectiveness and Safety Verification of Brinzolamide Combination Therapy on Primary Open-angle Glaucoma or Ocular Hypertension: A Systematic Review and Meta-analysis Study

이희영|김진아
한국임상약학회 (Korean College Of Clinical Pharmacy)|2021.09|한국임상약학회지 (Korean Journal of Clinical Pharmacy)|제31권 제3호|pp. 205-215|DOI https://doi.org/10.24304/kjcp.2021.31.3.205

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

glaucomaBrinzolamideocular hypertension
주제분류약학

초록

Background: The treatment of primary open-angle glaucoma (POAG) or ocular hypertension (OHT) for intraocular pressure (IOP)reduction is recommended to proceed with the use of the compound. Therefore, this study aimed to evaluate the efficacy and safetyof brinzolamide combination therapy on POAG and OHT following the subgroup analysis among types of brinzolamide combinedmedications. Methods: By June 2019, PubMed, EMBASE and Cochrane Library were searched to find a study that met our inclusioncriteria. Based on randomized control trials (RCTs), we collected studies that tested the brinzolamide combination therapy in POAGand OHT patients, and analyzed the literature identified by the results of the study on IOP reduction and adverse reactions. Results: Atotal of 13 literature was collected to conduct an analysis including 2,197 patients. The intervention included brinzolamidecombination therapies, combined with timolol, brimonidine, PGA or combined with both brimonidine and PGA. The analysisshowed significant decreasing tendency for values at morning and end treatment per day in the use of brinzolamide combinationtherapy in the absolute IOP change (mean difference (MD) −1.41; 95% CI −1.92, −0.90; p<0.001 vs. MD −1.46; 95% CI −2.03,−0.89; p<0.00001, respectively). We could see higher adverse reactions in the brinzolamide combination group using intervention(odds ratio 1.43; 95% CI 1.20, 1.71; p<0.0001). Conclusion: Regarding IOP reduction in POAG and OHT patients, brinzolamidecombination therapy is more effective but less safe than control treatment, which diverse among types of combined medications. Thus, more individualized therapy should be applied in real-world practice.

Abstract

Background: The treatment of primary open-angle glaucoma (POAG) or ocular hypertension (OHT) for intraocular pressure (IOP)reduction is recommended to proceed with the use of the compound. Therefore, this study aimed to evaluate the efficacy and safetyof brinzolamide combination therapy on POAG and OHT following the subgroup analysis among types of brinzolamide combinedmedications. Methods: By June 2019, PubMed, EMBASE and Cochrane Library were searched to find a study that met our inclusioncriteria. Based on randomized control trials (RCTs), we collected studies that tested the brinzolamide combination therapy in POAGand OHT patients, and analyzed the literature identified by the results of the study on IOP reduction and adverse reactions. Results: Atotal of 13 literature was collected to conduct an analysis including 2,197 patients. The intervention included brinzolamidecombination therapies, combined with timolol, brimonidine, PGA or combined with both brimonidine and PGA. The analysisshowed significant decreasing tendency for values at morning and end treatment per day in the use of brinzolamide combinationtherapy in the absolute IOP change (mean difference (MD) −1.41; 95% CI −1.92, −0.90; p<0.001 vs. MD −1.46; 95% CI −2.03,−0.89; p<0.00001, respectively). We could see higher adverse reactions in the brinzolamide combination group using intervention(odds ratio 1.43; 95% CI 1.20, 1.71; p<0.0001). Conclusion: Regarding IOP reduction in POAG and OHT patients, brinzolamidecombination therapy is more effective but less safe than control treatment, which diverse among types of combined medications. Thus, more individualized therapy should be applied in real-world practice.

참고문헌 (55)

  1. Resnikoff S, "Global data on visual impairment in the year 2002", Bull World Health Organ, 82(11), pp.844~851 (2004)
  2. Peters D, "Factors associated with lifetime risk of open-angle glaucoma blindness", Acta Ophthalmol, 92(5), pp.421~425 (2014)
  3. Tham YC, "Global prevalence of glaucoma and projections of glaucoma burden through 2040 : a systematic review and meta-analysis", Ophthalmology, 121(11), pp.2081~2090 (2014)
  4. Sharif NA, "Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision", Neural Regen Res, 13(7), pp.1145~1150 (2018)
  5. Weinreb RN, "The pathophysiology and treatment of glaucoma : a review", JAMA, 311(18), pp.1901~1911 (2014)
  6. "Terminology and guidelines for glaucoma" (2014)[URL]
  7. Nguyen QH, "Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension : critical appraisal and patient focus", Patient Prefer Adherence, 8, pp.853~864 (2014)
  8. Higginbotham EJ, "Considerations in glaucoma therapy : fixed combinations versus their component medications", Clin Ophthalmol, 4, pp.1~9 (2010)
  9. Ong SS, "Resident compliance with the american academy of ophthalmology preferred practice pattern guidelines for primary open-angle glaucoma", Ophthalmology, 120(12), pp.2462~2469 (2013)
  10. Nguyen QH, "The role of prostaglandin analogues in the treatment of glaucoma in the 21st century", Int Ophthalmol Clin, 44(2), pp.15~27 (2004)
  11. Iester M, "Brinzolamide ophthalmic suspension : a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension", Clin Ophthalmol, 2(3), pp.517~523 (2008)
  12. DeSantis L, "Preclinical overview of brinzolamide", Surv Ophthalmol, 44(Suppl 2), pp.S119~S129 (2000)
  13. Greig SL, "Brinzolamide", brimonidine : a review of its use in patients with open-angle glaucoma or ocular hypertension, 2015, pp.32(3), 251~260
  14. Webers CA, "Pharmacological management of primary open-angle glaucoma : second-line options and beyond", Drugs Aging, 25(9), pp.729~759 (2008)
  15. Cheng JW, "Systematic review of intraocular pressurelowering effects of adjunctive medications added to latanoprost", Ophthalmic Res, 42(2), pp.99~105 (2009)
  16. Dzhumataeva ZA, "Prostaglandin analogues in glaucoma treatment", Vestn Oftalmol, 132(4), pp.62~67 (2016)
  17. Lusthaus JA, "Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation", Expert Opin Drug Saf, 16(9), pp.1071~1078 (2017)
  18. Prum BE, Jr., "Primary open-angle glaucoma preferred practice pattern(®)Guidelines", Ophthalmology, 123(1), pp.P41~P111 (2016)
  19. "Glaucoma: diagnosis and management"[URL]
  20. Liu Y, "Efficacy and safety of brinzolamide as add-on to prostaglandin analogues or β-Blocker for glaucoma and ocular hypertension : A systematic review and metaanalysis", Front Pharmacol, 10, pp.679~ (2019)
  21. Joshi SR, "Evaluation of brimonidine-timolol fixed combination in patients of primary open-angle glaucoma", Indian J Ophthalmol, 61(12), pp.765~767 (2013)
  22. Craven ER, "Brimonidine and timolol fixed-combination therapy versus monotherapy : a 3-month randomized trial in patients with glaucoma or ocular hypertension", J Ocul Pharmacol Ther, 21(4), pp.337~348 (2005)
  23. Sherwood MB, "Twice-daily 0.2%brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial", Arch Ophthalmol, 124(9), pp.1230~1238 (2006)
  24. Knobloch K, "Preferred reporting items for systematic reviews and meta-analyses(PRISMA)statement and publication bias", J Craniomaxillofac Surg, 39(2), pp.91~92 (2011)
  25. Higgins JP, "The Cochrane Collaboration's tool for assessing risk of bias in randomised trials", BMJ, 343, pp.d5928~ (2011)
  26. Aihara M, "Additive effects and safety of fixed combination therapy with 1%brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5%timolol in prostaglandin-treated glaucoma patients", Acta Ophthalmol, 95(8), pp.e720~e726 (2017)
  27. Fechtner RD, "Ocular hypotensive effect of fixed-combination brinzolamide", brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial, 2016, pp.30(10), 1343~1350
  28. Michaud JE, "Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension", Am J Ophthalmol, 132(2), pp.235~243 (2001)
  29. Yoshikawa K, "Efficacy and safety of brinzolamide", timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension, 2014, pp.8, 389~399
  30. Aung T, "Twice-daily brinzolamide", brimonidine fixed combination versus brinzolamide or brimonidine in openangle glaucoma or ocular hypertension, 2014, pp.121(12), 2348~2355
  31. Feldman RM, "Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%", Ophthalmology, 114(7), pp.1248~1254 (2007)
  32. Feldman RM, "Realini T. A randomized trial of fixed-dose combination brinzolamide 1%", brimonidine 0.2% as adjunctive therapy to travoprost 0.004, 2016, pp.165, 188~197
  33. Holló G, "The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary openangle glaucoma", Eur J Ophthalmol, 16(6), pp.816~823 (2006)
  34. Kaback M, "Intraocular pressurelowering efficacy of brinzolamide 1%", timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%, 2008, pp.115(10), 1728~1734
  35. Nguyen QH, "Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%", brimonidine 0.2%, 2013, pp.29(3), 290~297
  36. Shin D, "Adjunctive therapy with brinzolamide 1% ophthalmic suspension(Azopt)in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy", Surv Ophthalmol, 44(Suppl 2), pp.S163~S168 (2000)
  37. Day DG, "Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension", Curr Med Res Opin, 24(5), pp.1435~1442 (2008)
  38. Katz G, "Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%", JAMA Ophthalmol, 131(6), pp.724~730 (2013)
  39. Kwon YH, "Primary openangle glaucoma", N Engl J Med, 360(11), pp.1113~1124 (2009)
  40. Kass MA, "The Ocular Hypertension Treatment Study : a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma", Arch Ophthalmol, 120(6), pp.701~713 (2002)
  41. Sommer A, "Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey", Arch Ophthalmol, 109(8), pp.1090~1095 (1991)
  42. Heijl A, "Reduction of intraocular pressure and glaucoma progression : results from the Early Manifest Glaucoma Trial", Arch Ophthalmol, 120(10), pp.1268~1279 (2002)
  43. Costagliola C, "Effect of 0.005%latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. Experience and incidence of side effects in a prospective study on 76 patients", Graefes Arch Clin Exp Ophthalmol, 240(5), pp.379~386 (2002)
  44. van der Valk R, "Intraocular pressure-lowering effects of all commonly used glaucoma drugs : a meta-analysis of randomized clinical trials", Ophthalmology, 112(7), pp.1177~1185 (2005)
  45. Shoji N, "Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study", Curr Med Res Opin, 21(4), pp.503~508 (2005)
  46. Miura K, "Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost", J Glaucoma, 17(3), pp.233~237 (2008)
  47. Puscas I, "Prostaglandins with vasodilating effects inhibit carbonic anhydrase while vasoconstrictive prostaglandins and leukotriens B4 and C4 increase CA activity", Int J Clin Pharmacol Ther, 33(3), pp.176~181 (1995)
  48. "Drug@FDA: FDA-Approved Drugs-SIMBRINZA"[URL]
  49. "SIMBRINZA ophthalmic suspension"[URL]
  50. Taniguchi T, "The potential systemic effect of topically applied beta-blockers in glaucoma therapy", Curr Opin Ophthalmol, 8(2), pp.55~58 (1997)
  51. Whitson JT, "Six-month results from a Phase III randomized trial of fixedcombination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension", Clin Ophthalmol, 7, pp.1053~1060 (2013)
  52. Silver LH, "Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group", Am J Ophthalmol, 126(3), pp.400~408 (1998)
  53. Topouzis F, "Brinzolamide", brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma, Eur J Ophthalmol, pp.2021, 31(1)[DOI]
  54. "AZOPT ophthalmic suspension (brinzolamide)"[URL]
  55. "Drug@FDA: FDA-Approved Drugs-AZOPT"[URL]

관련 논문AI추천

정상안압녹내장에서 브린졸라미드 1%와 티몰롤 0.5% 혼합제제의 효과김준모, 박한석, 배정훈, 최철영대한안과학회 · 대한안과학회지2014 · 제55권 제7호정상안압녹내장에서 브린졸라미드/브리모니딘 혼합제제의 효과신현욱, 진상욱대한안과학회 · 대한안과학회지2016 · 제57권 제10호한국인 정상안압녹내장에서 브린졸라미드 1%와 브리모니딘 0.2% 혼합제제의 임상 효과김인태, 김준모, 배정훈대한안과학회 · 대한안과학회지2018 · 제59권 제6호정상안압녹내장에서 브리모니딘-티몰롤 다회용 점안제와 일회용 점안제의 효과 및 안정성 분석김보경, 김시내, 김준모대한안과학회 · 대한안과학회지2021 · 제62권 제10호Comparison of Two Combinations of Maximum Medical Therapy for Lowering Intraocular Pressure in Primary Open-angle Glaucoma김영국, 박기호, 위서영, 정진욱, 하아늘대한안과학회 · Korean Journal of Ophthalmology2020 · 제34권 제1호도졸라마이드/티몰롤 혼합 제제를 사용 중인 원발개방각녹내장에서 프로스타글란딘 제제 추가 시 효과이재훈, 진상욱대한안과학회 · 대한안과학회지2022 · 제63권 제8호

이 간행물의 다른 논문 (7건)

유럽의 규제과학 및 규제과학 인재양성 프로젝트김지원, 백다정, 박재홍, 최영욱, 김은영, 정선영, 이윤지, 김하형, 신호철, 강원구pp. 171-179비스포스포네이트 제제 관련 관절통 및 근육통에 대한 지역 약국 약사 및 환자 능동적 모니터링송정우, 이정민, 김나영, 김영욱, 이주연, 신주영, 박소희, 윤동원, 이모세pp. 180-187PD-1 억제제의 사용패턴 및 갑상선 관련 유해사례 발현 양상 분석서동철, 민명숙, 황서영, 정선영, 김희재pp. 188-197국내 성인환자에서 죽상동맥경화성 심혈관질환 위험도와 스타틴 처방 현황김종윤, 유기연pp. 198-204한국과 영국의 건강불평등 국가 데이터베이스 비교: 중독 물질 오남용 관련 정신건강 및 호흡기 질환을 중심으로이인향pp. 216-230
원문 보기